DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL

Inclusion Criteria: Inclusion Criteria for DA-EPOCH-R induction: * High-grade B-cell lymphoma, with MYC in combination with BCL2 and/or BCL6 rearrangements as assessed by fluorescence in situ hybridization (FISH) according to the WHO 2016 classification including high-grade B-cell lymphoma with MYC and BCL2 rearrangements, transformed from previously untreated FL. * Age ≥ 18 year. * Patient started with or has received one course of full dose R-CHOP. \[Reversed R-CHOP (cyclophosphamide, vincristine and doxorubicin on day 5) is allowed; local radiation or short course (max 7 days) of steroids (max 100 mg/day) before R-CHOP is allowed. Mini-R-CHOP is not allowed\]. * World Health Organization (WHO) performance status 0-3 during or after the first R-CHOP cycle. * Ann Arbor stage II-IV at diagnosis. * 18F-FDG PET scan and contrast enhanced CT-scan performed within 21 days before start first cycle of R-CHOP. * Measurable disease: on contrast enhanced CT-scan at least 1 lesion/node with a long axis of \>1.5 cm and at least one 18F-FDG avid lesion. * Negative pregnancy test at study entry. * Patient is willing and able to use adequate contraception until 6 months post last treatment administration. * Written informed consent. * Patient is capable of giving informed consent. Inclusion criteria for Nivolumab consolidation: * Complete metabolic response on end of induction 18F-FDG PET-CT assessed with the Deauville response criteria * Patient has completed at least R-CHOP plus four…